La vendita allo scoperto per DexCom dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di DexCom. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

DexCom (NASDAQ:DXCM) Azioni, Report sulle vendite allo scoperto

DexCom

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Long Ideas

News

Markets

Media

Trading Ideas

COST

CRSP

DLTR

DXCM

Jim Cramer consiglia di acquistare Oneok, elogiando i risultati eccellenti e il potenziale di crescita della società.

Jim Cramer: questo titolo è un vero e proprio affare!

DexCom Inc

DEXCOM ORD

High-rolling investors have positioned themselves bullish on DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in DXCM often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for DexCom. This is not a typical pattern.
The sentiment among these major traders is split, with 37% bullish and 37% bearish. Among all the options we identified, there was one put, amounting to $27,282, and 7 calls, totaling $661,740.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $70.0 and $115.0 for DexCom, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of DexCom stands at 764.62, with a total volume reaching 799.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in DexCom, situated within the strike price corridor from $70.0 to $115.0, throughout the last 30 days.
<h3>DexCom 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729267267_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$8.5</td>
<td>$8.3</td>
<td>$8.4</td>
<td>$70.00</td>
<td>$197.4K</td>
<td>1.5K</td>
<td style="text-align: right;">245</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.2</td>
<td>$6.1</td>
<td>$6.2</td>
<td>$75.00</td>
<td>$143.8K</td>
<td>855</td>
<td style="text-align: right;">286</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$14.3</td>
<td>$14.0</td>
<td>$14.3</td>
<td>$80.00</td>
<td>$127.2K</td>
<td>119</td>
<td style="text-align: right;">90</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$4.1</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$80.00</td>
<td>$80.0K</td>
<td>362</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$23.6</td>
<td>$22.8</td>
<td>$23.2</td>
<td>$70.00</td>
<td>$46.4K</td>
<td>99</td>
<td style="text-align: right;">20</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Following our analysis of the options activities associated with DexCom, we pivot to a closer look at the company's own performance.
<h3>DexCom's Current Market Status</h3>
<ul>
<li>With a volume of 1,238,195, the price of DXCM is down -0.24% at $69.38. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 6 days.</li>
</ul>
<h3>Expert Opinions on DexCom</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $120.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on DexCom with a target price of $120. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DexCom options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Behind the Scenes of DexCom's Latest Options Trends

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$116.00</td>
<td>$116.9K</td>
<td>3.7K</td>
<td>3.7K</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$100.00</td>
<td>$66.3K</td>
<td>2.4K</td>
<td>1.6K</td>
</tr>
<tr>
<td>MOH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$330.00</td>
<td>$156.4K</td>
<td>55</td>
<td>720</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.00</td>
<td>$77.0K</td>
<td>3</td>
<td>550</td>
</tr>
<tr>
<td>EWTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$35.00</td>
<td>$30.0K</td>
<td>16</td>
<td>300</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/25/24</td>
<td>$27.50</td>
<td>$29.0K</td>
<td>145</td>
<td>293</td>
</tr>
<tr>
<td>SMMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$20.00</td>
<td>$53.0K</td>
<td>293</td>
<td>246</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$60.00</td>
<td>$76.5K</td>
<td>1.1K</td>
<td>120</td>
</tr>
<tr>
<td>GPCR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$40.00</td>
<td>$121.0K</td>
<td>175</td>
<td>100</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/01/24</td>
<td>$275.00</td>
<td>$31.5K</td>
<td>590</td>
<td>68</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a put option trade with neutral sentiment. It expires in 2 day(s) on October 18, 2024. Parties traded 2924 contract(s) at a $116.00 strike. The total cost received by the writing party (or parties) was $116.9K, with a price of $40.0 per contract. There were 3761 open contracts at this strike prior to today, and today 3738 contract(s) were bought and sold. 
• Regarding DXCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), we observe a call option sweep with bearish sentiment. It expires in 93 day(s) on January 17, 2025. Parties traded 603 contract(s) at a $100.00 strike. This particular call needed to be split into 81 different trades to become filled. The total cost received by the writing party (or parties) was $66.3K, with a price of $110.0 per contract. There were 2415 open contracts at this strike prior to today, and today 1605 contract(s) were bought and sold. 
• Regarding MOH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), we observe a call option trade with bullish sentiment. It expires in 2 day(s) on October 18, 2024. Parties traded 549 contract(s) at a $330.00 strike. The total cost received by the writing party (or parties) was $156.4K, with a price of $285.0 per contract. There were 55 open contracts at this strike prior to today, and today 720 contract(s) were bought and sold. 
• Regarding CAPR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), we observe a call option trade with bearish sentiment. It expires in 247 day(s) on June 20, 2025. Parties traded 50 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $77.0K, with a price of $1540.0 per contract. There were 3 open contracts at this strike prior to today, and today 550 contract(s) were bought and sold. 
• Regarding EWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>), we observe a put option sweep with bearish sentiment. It expires in 2 day(s) on October 18, 2024. Parties traded 300 contract(s) at a $35.00 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $30.0K, with a price of $100.0 per contract. There were 16 open contracts at this strike prior to today, and today 300 contract(s) were bought and sold. 
• Regarding SAVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), we observe a call option trade with bullish sentiment. It expires in 9 day(s) on October 25, 2024. Parties traded 100 contract(s) at a $27.50 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $290.0 per contract. There were 145 open contracts at this strike prior to today, and today 293 contract(s) were bought and sold. 
• Regarding SMMT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>), we observe a call option trade with neutral sentiment. It expires in 30 day(s) on November 15, 2024. Parties traded 100 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $53.0K, with a price of $530.0 per contract. There were 293 open contracts at this strike prior to today, and today 246 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bullish, expiring in 93 day(s) on January 17, 2025. This event was a transfer of 50 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $76.5K, with a price of $1530.0 per contract. There were 1168 open contracts at this strike prior to today, and today 120 contract(s) were bought and sold. 
• For GPCR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>), we notice a call option trade that happens to be bullish, expiring in 429 day(s) on December 19, 2025. This event was a transfer of 100 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $121.0K, with a price of $1210.0 per contract. There were 175 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• For HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we notice a call option trade that happens to be bearish, expiring in 16 day(s) on November 1, 2024. This event was a transfer of 60 contract(s) at a $275.00 strike. The total cost received by the writing party (or parties) was $31.5K, with a price of $526.0 per contract. There were 590 open contracts at this strike prior to today, and today 68 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAPR

EWTX

GPCR

SAVA

SMMT

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

DexCom's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NYSE">DXCM</a>) short percent of float has risen 16.43% since its last report. The company recently reported that it has 8.55 million shares sold short, which is 2.41% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.27 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>DexCom Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728489614_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for DexCom has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing DexCom's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, DexCom's peer group average for short interest as a percentage of float is 4.34%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into DexCom's Recent Short Interest

RBC Capital analyst Shagun Singh maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Outperform and lowers the price target from $130 to $120.

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on DexCom, Lowers Price Target to $120

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 15 years by 15.26% on an annualized basis producing an average annual return of 26.92%. Currently, DexCom has a market capitalization of $27.67 billion. 
Buying $100 In DXCM: If an investor had bought $100 of DXCM stock 15 years ago, it would be worth $3,619.92 today based on a price of $69.05 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728403225_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth $3,600 Today

Investors with a lot of money to spend have taken a bullish stance on DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with DXCM, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for DexCom.
This isn't normal.
The overall sentiment of these big-money traders is split between 80% bullish and 10%, bearish.
Out of all of the options we uncovered, 9 are puts, for a total amount of $403,590, and there was 1 call, for a total amount of $28,000.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $45.0 to $80.0 for DexCom over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in DexCom's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to DexCom's substantial trades, within a strike price spectrum from $45.0 to $80.0 over the preceding 30 days.
<h3>DexCom Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728319557_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$18.0</td>
<td>$17.7</td>
<td>$18.0</td>
<td>$75.00</td>
<td>$117.0K</td>
<td>246</td>
<td style="text-align: right;">66</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$3.8</td>
<td>$3.6</td>
<td>$3.6</td>
<td>$45.00</td>
<td>$54.0K</td>
<td>4</td>
<td style="text-align: right;">150</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$14.9</td>
<td>$14.8</td>
<td>$14.8</td>
<td>$80.00</td>
<td>$39.9K</td>
<td>2.6K</td>
<td style="text-align: right;">27</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$14.8</td>
<td>$14.6</td>
<td>$14.6</td>
<td>$80.00</td>
<td>$36.5K</td>
<td>2.6K</td>
<td style="text-align: right;">52</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$13.8</td>
<td>$13.8</td>
<td>$13.8</td>
<td>$70.00</td>
<td>$35.8K</td>
<td>2</td>
<td style="text-align: right;">47</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Having examined the options trading patterns of DexCom, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>DexCom's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,519,451, with DXCM's price up by 0.82%, positioned at $68.67.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 17 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DexCom options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

This Is What Whales Are Betting On DexCom

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 15 years by 14.45% on an annualized basis producing an average annual return of 26.36%. Currently, DexCom has a market capitalization of $27.15 billion. 
Buying $100 In DXCM: If an investor had bought $100 of DXCM stock 15 years ago, it would be worth $3,262.77 today based on a price of $67.76 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727717412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In DexCom 15 Years Ago Would Be Worth This Much Today

Investors with a lot of money to spend have taken a bullish stance on DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DXCM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for DexCom.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 44%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $346,714, and 3 are calls, for a total amount of $110,992.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $50.0 and $100.0 for DexCom, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for DexCom options trades today is 476.12 with a total volume of 901.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for DexCom's big money trades within a strike price range of $50.0 to $100.0 over the last 30 days.
<h3>DexCom 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727381809_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$6.8</td>
<td>$6.5</td>
<td>$6.6</td>
<td>$55.00</td>
<td>$165.0K</td>
<td>0</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$12.3</td>
<td>$12.1</td>
<td>$12.3</td>
<td>$70.00</td>
<td>$71.3K</td>
<td>471</td>
<td style="text-align: right;">58</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$4.2</td>
<td>$4.1</td>
<td>$4.2</td>
<td>$75.00</td>
<td>$50.4K</td>
<td>645</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$15.6</td>
<td>$15.2</td>
<td>$15.44</td>
<td>$70.00</td>
<td>$30.8K</td>
<td>73</td>
<td style="text-align: right;">21</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$2.75</td>
<td>$2.7</td>
<td>$2.72</td>
<td>$60.00</td>
<td>$29.9K</td>
<td>1.0K</td>
<td style="text-align: right;">146</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
After a thorough review of the options trading surrounding DexCom, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of DexCom</h3>
<ul>
<li>With a volume of 3,204,425, the price of DXCM is up 1.2% at $67.53. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 28 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DexCom options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

What the Options Market Tells Us About DexCom

Investors with a lot of money to spend have taken a bullish stance on DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DXCM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for DexCom.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 25%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $176,999, and 4 are calls, for a total amount of $148,385.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $75.0 for DexCom, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of DexCom stands at 890.12, with a total volume reaching 1,305.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in DexCom, situated within the strike price corridor from $55.0 to $75.0, throughout the last 30 days.
<h3>DexCom Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726678146_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$11.8</td>
<td>$11.6</td>
<td>$11.6</td>
<td>$65.00</td>
<td>$62.6K</td>
<td>929</td>
<td style="text-align: right;">271</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.8</td>
<td>$5.5</td>
<td>$5.5</td>
<td>$65.00</td>
<td>$59.9K</td>
<td>1.1K</td>
<td style="text-align: right;">548</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$10.3</td>
<td>$10.1</td>
<td>$10.2</td>
<td>$75.00</td>
<td>$44.8K</td>
<td>617</td>
<td style="text-align: right;">45</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.8</td>
<td>$7.5</td>
<td>$7.7</td>
<td>$55.00</td>
<td>$39.2K</td>
<td>122</td>
<td style="text-align: right;">54</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$7.8</td>
<td>$7.7</td>
<td>$7.8</td>
<td>$70.00</td>
<td>$35.1K</td>
<td>1.3K</td>
<td style="text-align: right;">45</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
After a thorough review of the options trading surrounding DexCom, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>DexCom's Current Market Status</h3>
<ul>
<li>With a volume of 1,428,567, the price of DXCM is up 1.31% at $69.84. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 36 days.</li>
</ul>
<h3>Expert Opinions on DexCom</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $95.0.
<ul>
<li>An analyst from Piper Sandler downgraded its action to Overweight with a price target of $90. </li>
<li>An analyst from Stifel persists with their Buy rating on DexCom, maintaining a target price of $100. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for DexCom with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Unpacking the Latest Options Trading Trends in DexCom

<ul>
<li>While in orbit, the Polaris Dawn crew will conduct scientific research designed to advance both human health on Earth and our understanding of human health during long-duration spaceflights. Given that one in ten1 people globally live with diabetes, it's essential to understand the impact of space travel on human health to ensure it is accessible and inclusive of all people, including those living with diabetes and other chronic health conditions.</li>
<li>Over their five days in space, the Polaris Dawn crew will conduct around 40 scientific experiments, including several to better understand the effects of spaceflight on glucose health. <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.labfront.com%2F&amp;esheet=54114343&amp;newsitemid=20240827030657&amp;lan=en-US&amp;anchor=Labfront&amp;index=2&amp;md5=5af47c319ca2d55c537a7a0f4992a874">Labfront</a>, a platform assisting health researchers in collecting and analyzing physiological data, is collaborating with Dexcom to provide advanced analytics for the data collected using Dexcom CGM. The research will explore how microgravity, fluid shifts, and blood flow restriction exercises impact glucose regulation.</li>
</ul>

Health Care

General

DexCom Announced The Dexcom G6 Continuous Glucose Monitoring System Is Being Worn By Astronauts In Space As Part Of The Polaris Dawn Mission

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 15 years by 15.25% on an annualized basis producing an average annual return of 26.82%. Currently, DexCom has a market capitalization of $28.42 billion. 
Buying $100 In DXCM: If an investor had bought $100 of DXCM stock 15 years ago, it would be worth $3,460.00 today based on a price of $70.93 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725899411_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said he prefers Royal Caribbean (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) over Carnival Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) .
&#8220;Royal Caribbean has the best systems right now, it's got the best numbers. It's the one you want, not Carnival,&#8221; he added.
On Aug. 27, Carnival unveiled new itineraries for seven ships sailing in 2026 and 2027 from Miami, Port Canaveral, Galveston, and Baltimore.
EPR Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>) has been<a href="https://www.benzinga.com/quote/EPR/earnings"> &#8220;too rocky&#8221; for Cramer.</a> On July 31, EPR Properties posted better-than-expected sales for its second quarter.
Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) is &#8220;too inconsistent,&#8221; Cramer said. &#8220;They don't get my buy with that level of inconsistency.&#8221;
On Aug. 19, Whirlpool declared a quarterly dividend of $1.75 per share on its common stock.
When asked about DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), he said, &#8220;I did not really care for that last quarter or the explanation of why things had slowed.&#8221;
On Aug. 26, Piper Sandler analyst Matt O&#8217;Brien reiterated DexCom with an Overweight rating and maintained a $90 price target.
The &#8220;Mad Money&#8221; host said he really liked SpartanNash Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPTN#NASDAQ">SPTN</a>). &#8220;I like that dividend,&#8221; he added.
On Aug. 15, SpartanNash reported second-quarter adjusted earnings per share of 59 cents, beating the street view of 56 cents. Quarterly revenues of $2.23 billion missed the analyst consensus of $2.27 billion.
Price Action:
<ul>
<li>EPR Properties shares fell 0.5% to settle at $47.72 on Thursday.</li>
<li>Carnival shares closed at $16.15 during Thursday's session.</li>
<li>Whirlpool shares fell 1.3% to close at $97.53 during Thursday's session.</li>
<li>Dexcom shares fell 1.1% to settle at $69.05 on Thursday.</li>
<li>SpartanNash shares fell 1.9% to settle at $22.12 during the session.</li>
</ul>
Read Next:<a href="https://www.benzinga.com/top-stories/24/09/40730015/jim-cramer-oklo-is-losing-money-hand-over-fist-but-this-private-equity-stock-is-a-buy"> </a>
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40730015/jim-cramer-oklo-is-losing-money-hand-over-fist-but-this-private-equity-stock-is-a-buy">Jim Cramer: Oklo Is Losing Money &#8216;Hand-Over-Fist,&#8217; But This Private Equity Stock Is A Buy</a></li>
</ul>
Image: Shutterstock

Travel

SPTN

Jim Cramer Doesn't Like Carnival Right Now: Royal Caribbean Is 'The One You Want'

Investors with a lot of money to spend have taken a bearish stance on DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DXCM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for DexCom.
This isn't normal.
The overall sentiment of these big-money traders is split between 33% bullish and 55%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $213,146, and 3 are calls, for a total amount of $154,020.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $65.0 to $135.0 for DexCom over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of DexCom stands at 567.88, with a total volume reaching 2,675.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in DexCom, situated within the strike price corridor from $65.0 to $135.0, throughout the last 30 days.
<h3>DexCom Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725393656_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$9.9</td>
<td>$9.7</td>
<td>$9.7</td>
<td>$70.00</td>
<td>$96.9K</td>
<td>438</td>
<td>224</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/06/24</td>
<td>$0.95</td>
<td>$0.55</td>
<td>$0.89</td>
<td>$70.00</td>
<td>$56.4K</td>
<td>2.0K</td>
<td>1.0K</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$62.9</td>
<td>$61.8</td>
<td>$62.41</td>
<td>$135.00</td>
<td>$37.4K</td>
<td>37</td>
<td>6</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/06/24</td>
<td>$0.95</td>
<td>$0.85</td>
<td>$0.85</td>
<td>$70.00</td>
<td>$36.8K</td>
<td>2.0K</td>
<td>439</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$10.5</td>
<td>$10.4</td>
<td>$10.5</td>
<td>$70.00</td>
<td>$31.5K</td>
<td>339</td>
<td>5</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Following our analysis of the options activities associated with DexCom, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of DexCom</h3>
<ul>
<li>Currently trading with a volume of 3,961,087, the DXCM's price is up by 4.3%, now at $72.33. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 51 days.</li>
</ul>
<h3>What The Experts Say On DexCom</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $90.66666666666667.
<ul>
<li>Maintaining their stance, an analyst from Baird continues to hold a Neutral rating for DexCom, targeting a price of $82. </li>
<li>In a cautious move, an analyst from Piper Sandler downgraded its rating to Overweight, setting a price target of $90. </li>
<li>An analyst from Stifel persists with their Buy rating on DexCom, maintaining a target price of $100. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for DexCom with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Spotlight on DexCom: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bearish stance on DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with DXCM, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 11 options trades for DexCom.
This isn't normal.
The overall sentiment of these big-money traders is split between 27% bullish and 63%, bearish.
Out of all of the options we uncovered, 10 are puts, for a total amount of $606,156, and there was 1 call, for a total amount of $391,000.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $60.0 to $75.0 for DexCom during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of DexCom stands at 398.14, with a total volume reaching 11,462.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in DexCom, situated within the strike price corridor from $60.0 to $75.0, throughout the last 30 days.
<h3>DexCom Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725036408_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$4.7</td>
<td>$4.5</td>
<td>$4.6</td>
<td>$75.00</td>
<td>$390.9K</td>
<td style="text-align: right;">544</td>
<td>861</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/06/24</td>
<td>$1.65</td>
<td>$0.9</td>
<td>$1.55</td>
<td>$70.00</td>
<td>$132.8K</td>
<td style="text-align: right;">105</td>
<td>857</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.8</td>
<td>$6.7</td>
<td>$6.8</td>
<td>$60.00</td>
<td>$80.9K</td>
<td style="text-align: right;">593</td>
<td>89</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/06/24</td>
<td>$1.7</td>
<td>$1.4</td>
<td>$1.4</td>
<td>$69.00</td>
<td>$62.4K</td>
<td style="text-align: right;">394</td>
<td>54</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/06/24</td>
<td>$2.3</td>
<td>$2.1</td>
<td>$2.25</td>
<td>$70.00</td>
<td>$56.2K</td>
<td style="text-align: right;">105</td>
<td>2.5K</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Having examined the options trading patterns of DexCom, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of DexCom</h3>
<ul>
<li>Currently trading with a volume of 1,665,804, the DXCM's price is up by 0.3%, now at $69.83. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 55 days.</li>
</ul>
<h3>What The Experts Say On DexCom</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $90.66666666666667.
<ul>
<li>In a cautious move, an analyst from Piper Sandler downgraded its rating to Overweight, setting a price target of $90. </li>
<li>An analyst from Baird has decided to maintain their Neutral rating on DexCom, which currently sits at a price target of $82. </li>
<li>Maintaining their stance, an analyst from Stifel continues to hold a Buy rating for DexCom, targeting a price of $100. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for DexCom with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

DexCom Unusual Options Activity For August 30

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 15 years by 15.18% on an annualized basis producing an average annual return of 27.38%. Currently, DexCom has a market capitalization of $29.14 billion. 
Buying $1000 In DXCM: If an investor had bought $1000 of DXCM stock 15 years ago, it would be worth $37,830.95 today based on a price of $72.73 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724781611_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $38,000 Today

Piper Sandler analyst Matt O'Brien reiterates DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Overweight and maintains $90 price target.

Reiteration

Piper Sandler Reiterates Overweight on DexCom, Maintains $90 Price Target

In March, the FDA approved DexCom Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) Stelo Glucose Biosensor System as the first over-the-counter (OTC) <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37522301/fda-approval-for-dexcoms-stelo-opens-continuous-glucose-monitoring-to-masses-analys" target="_blank" rel="noreferrer noopener">continuous glucose monitor (CGM)</a>. 
The Dexcom Stelo Glucose Biosensor System is an integrated CGM (iCGM) intended for people 18 and older who do not use insulin.
On Monday, DexCom announced Stelo is now available for purchase without a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40547929/stelo-by-dexcom-the-first-over-the-counter-glucose-biosensor-in-the-u-s-is-now-available" rel="noreferrer noopener">prescription&nbsp;at&nbsp;Stelo.com</a>.
Stelo is a small biosensor worn on the back of the upper arm.
It is specifically designed to provide the 125 million Americans&nbsp;with Type 2 diabetes who are not using insulin and those with&nbsp;prediabetes with personalized glucose insights sent directly to their smartphones.
These insights reveal how food, exercise, and sleep can affect glucose—all without painful fingersticks.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39861919/abbott-labs-makes-marketing-push-for-new-glucose-monitors-targets-health-conscious-consumers" rel="noreferrer noopener">Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers</a>.
Users can buy a one-month supply online for $99 (for a single pack of two sensors (total wear time up to 30 days) or sign up for an ongoing subscription at $89 a month.
In June, the FDA approved two new over-the-counter continuous glucose monitoring (CGM) systems from Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): Lingo and Libre Rio. These systems are based on Abbott&#8217;s FreeStyle Libre technology, which is now used by about <a href="https://www.benzinga.com/pressreleases/24/06/n39248164/abbott-receives-u-s-fda-clearance-for-two-new-over-the-counter-continuous-glucose-monitoring-syste" target="_blank" rel="noreferrer noopener">6 million people globally</a>.
Reuters noted that Lingo has been available in Britain since January for $152-$190 (120-150 pounds) per month.
Jake Leach, chief operating officer at Dexcom, told CNBC in an <a href="https://www.cnbc.com/2024/08/26/dexcom-launches-stelo-its-first-over-the-counter-continuous-glucose-monitor.html" target="_blank" rel="noreferrer noopener">interview</a> that Dexcom is working with Amazon to fulfill Stelo deliveries.
Dexcom said patients also have the option to use their flexible spending accounts and health savings accounts to pay for Stelo, CNBC noted.
Stelo is a small, gray device worn on the upper arm, about the size of a quarter and half an inch thick, with a 15-day lifespan before needing replacement. It wirelessly transmits data to a smartphone app, where users specify whether they have Type 2 diabetes, prediabetes, or neither. This information sets a &#8220;Target Range&#8221; for maintaining optimal glucose levels.
Price Action: DXCM stock is up 0.48% at $74.43 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/08/40553848/baker-hughes-says-us-oil-and-gas-rig-count-declines-for-second-week-report" target="_blank" rel="noreferrer noopener">Baker Hughes Says US Oil And Gas Rig Count Declines For Second Week: Report</a></li>
</ul>
Photo: Shutterstock

Large Cap

Dexcom's Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients

<ul>
<li>Available for purchase today at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.stelo.com%2F&amp;esheet=54113088&amp;newsitemid=20240826019839&amp;lan=en-US&amp;anchor=Stelo.com&amp;index=1&amp;md5=88ec3e10c5b5ed9720b0313dc0d9d3b3">Stelo.com</a> for people in the U.S. 18 and older not using insulin</li>
<li>Provides 24/7 powerful and personalized glucose insights directly to a smartphone,&#x2A; revealing how food, exercise and sleep can affect glucose</li>
<li>Tracking glucose just got easier, with no prescription and no fingersticks, ever</li>
<li>Specifically designed to help people with Type 2 diabetes not using insulin and those with prediabetes reach their A1c goals and potentially slow the progression of diabetes.†,1-3</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dexcom.com%2F&amp;esheet=54113088&amp;newsitemid=20240826019839&amp;lan=en-US&amp;anchor=DexCom&amp;index=2&amp;md5=28c454b72f7497850576697e9d205572">DexCom</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter glucose biosensor in the U.S., is now available for purchase without a prescription4 at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.stelo.com%2F&amp;esheet=54113088&amp;newsitemid=20240826019839&amp;lan=en-US&amp;anchor=Stelo.com&amp;index=3&amp;md5=9d7cfb8954a62f0aed2c095b05181991">Stelo.com</a>.

Biotech

Reported Earlier, Dexcom Announces Stelo, The First Over-The-Counter Glucose Biosensor In The U.S., Is Now Available For Purchase Without A Prescription

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has been analyzed by 18 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $104.22, a high estimate of $145.00, and a low estimate of $75.00. A 24.99% drop is evident in the current average compared to the previous average price target of $138.94. 
<img src="https://www.benzinga.com/files/images/story/2024/1724414501_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of DexCom by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$82.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$113.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$95.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$89.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$145.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$132.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Issie Kirby</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Neutral</td>
<td>$130.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to DexCom. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of DexCom compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for DexCom's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of DexCom's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DexCom analyst ratings.</a>
<h2>Discovering DexCom: A Closer Look</h2>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>DexCom's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, DexCom showcased positive performance, achieving a revenue growth rate of 15.26% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: DexCom's net margin excels beyond industry benchmarks, reaching 14.29%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): DexCom's ROE stands out, surpassing industry averages. With an impressive ROE of 6.13%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): DexCom's ROA excels beyond industry benchmarks, reaching 2.16%. This signifies efficient management of assets and strong financial health.
Debt Management: DexCom's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.07, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 18 Analyst Evaluations For DexCom

Stifel analyst Mathew Blackman maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $90 to $100.

Stifel Maintains Buy on DexCom, Raises Price Target to $100

Top movers as S&P 500 clocks another quarter of record growth

How is VOO stock faring? The Vanguard S&P 500 ETF is down 0.76% in the past five days but has risen 35.68% over the past year.  According to TipRan...

VOO ETF Update, 10/2/2024

Bristol-Myers tops growth chart among S&P 500 healthcare stocks in Q3

Medical device maker DexCom ($DXCM) operates in a highly competitive market for continuous glucose monitoring (CGM) systems, with players competing...

DexCom Stock Remains a "Strong Buy" Despite Fierce Competition

Wolfe's tax loss selling stocks within communications, discretionary, staples, energy, financials, health care

The Bull's Biggest Hits And Misses

How is QQQ stock faring? The Invesco QQQ ETF is up 0.03% in the past five days and has risen about 22.01% year-to-date.   According to TipRanks' un...

QQQ ETF Update, 10/16/2024

DexCom Q3 Preview: Walking On Eggshells With Its Channel Relationships

The S&P 500 election-year implied return from now until year-end reaches 6,200 – analyst

Baron Health Care Fund Q3 2024 Shareholder Letter

ACHC

ACLX

ALLE

ANET

APLS

APTV

ARGNF

ARGX

ASML

AVGO

AXON

BBWI

BCAP

BIIB

BKNG

BLDR

BMRN

BMYMP

BROE

CBRE

CELH

CHTR

CRWD

DELL

ENPH

EPAM

ERIE

ETSY

EXPD

FICO

FIVE

FOXF

FTNT

ICLR

INSM

INTC

IONS

IRDM

IRTC

ISRG

JBHT

LCID

LRCX

LULU

MBLY

MRNA

NFLX

NVDA

NVST

NYCB

PARA

PAYC

PCVX

PLTR

PRGO

PTEN

QDEL

RARE

RDNT

REGN

RGEN

RIVN

SIRI

SMCI

SNAP

SOLV

TSLA

UBER

ULTA

VRTX

XLRE

XRAY

Screenshot 2024-10-03 at 5.30.47 PM

GCTK

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-08-23 at 5.43.44 PM

Poster Presentations, Upcoming Human Trials, Recently Secured Funding And More: Glucotrack&#39;s Plans To Transform The Continuous Glucose Monitoring Market

Movers & Shakers

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

Press Releases

DXCM Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. (DXCM) Investors of Filing Deadline in Class Action Lawsuit

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DexCom, Inc. (DXCM)

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against DexCom, Inc. - DXCM

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit

Legal

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important October 21 Deadline in Securities Class Action – DXCM

SHAREHOLDER ALERT: Holzer & Holzer, LLC Reminds Investors of the October 21, 2024 Lead Plaintiff Deadline in Class Action Lawsuits Filed on Behalf of DexCom, Inc. (DXCM), Orthofix Medical Inc. (OFIX), and Spire Global, Inc. (SPIR) Shareholders

TUESDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - DXCM

DXCM Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc.  (DXCM) Investors of Filing Deadline in Class Action Lawsuit

RLF Urges DexCom, Inc. (NASDAQ: DXCM) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Comments

DexCom

Vendite allo scoperto

DexCom (NASDAQ:DXCM) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO